Strong sales, expanded product line, and more in the pipeTop line growth of 24% and earnings of $0.0125 per fully diluted share show the company is continuing to grow after what looked like a plateau over the past few quarters.
The starategy of expanding their product line with the CovaWound products makes Covalon a more atttractive supplier to international distributors looking to carry a more complete product line of advanced wound care products.
The new facility is for the pilot production and scale-up of more new products, which wouldn't be economical to send directly to contract manufacturing.
Things are on track here and I like the business they are building, with the continued potential for more big licensing agreements.